Thalidomide in Treating Patients With Relapsed or Progressive Systemic Mastocytosis
Status:
Completed
Trial end date:
2012-10-01
Target enrollment:
Participant gender:
Summary
RATIONALE: Thalidomide may stop the growth of systemic mastocytosis by blocking blood flow to
the disease.
PURPOSE: This phase II trial is studying how well thalidomide works in treating patients with
relapsed or progressive systemic mastocytosis.